PRESS RELEASE February 28, 2013

EpiCept Reports Fourth Quarter and Full Year 2012 Operating and Financial Results

TARRYTOWN, N.Y.–(BUSINESS WIRE)– Regulatory News: EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT) today announced operating and financial results for the fourth quarter and full year ended December 31, 2012, and provided an update on the Company’s merger with Immune Pharmaceuticals, Ltd. (Immune). Robert Cook, Interim President and CEO of EpiCept, commented, “While we […]

Keep Reading

NEWS February 25, 2013

Immune Pharmaceuticals starts a phase II clinical trial in Ulcerative Colitis- The Marker

February 25, 2013 http://www.themarker.com/markets/1.1937849 Immune Pharma, which plans to merge with Epicept, initiates the clinical trial after receiving the approval of the Ministry of Health   Immune Pharmaceuticals, which plans to merge with Epicept, began Phase II Clinical Trials with Bertilimumab, a new drug developped for the treatment of Ulcerative Colitis after receiving the approval […]

Keep Reading

February 21, 2013

Immune Initiates Bertilimumab Phase II Clinical Trial in Ulcerative Colitis

February 21, 2013 Bertilimumab Targets Eotaxin-1, a Chemokine Over-Expressed in Ulcerative Colitis Patients IMMUNE Pharmaceuticals – 15 Aba Even Avenue, 2nd Floor, Herzliya-Pituach, 46733, Israel • Serge Goldner, CFO, tel: +972 9 886-6612, email: serge.goldner@immunepharma.com • (New York Office) Ms. Anna Baran, Director, Corporate Development, tel: +1 (646) 937-1941, email:anna.baran@immunepharma.com EpiCept Corporation – 777 Old Saw […]

Keep Reading

PRESS RELEASE February 21, 2013

Immune Initiates Bertilimumab Phase II Clinical Trial in Ulcerative Colitis

HERZLIYA-PITUACH, Israel & TARRYTOWN, N.Y.–(BUSINESS WIRE)– Regulatory News: Immune Pharmaceuticals Ltd. (“Immune”), a privately held Israeli company, and EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT) announced today that Immune is initiating, following authorization from Israeli health authorities, a Phase II double-blind placebo controlled study with its lead drug, bertilimumab, in patients with moderate-to-severe […]

Keep Reading

February 12, 2013

EpiCept Corporation and Immune Pharmaceuticals Amend Merger Agreement

February 12, 2013   IMMUNE TO PROVIDE EPICEPT WITH UP TO $0.5 MILLION IN WORKING CAPITAL   HERZLIYA-PITUACH, Israel & TARRYTOWN, N.Y.–(BUSINESS WIRE)– Regulatory News: Immune Pharmaceuticals Ltd. (“Immune”), a privately held Israeli company, and EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT) announced today that they have executed an amendment to the Merger […]

Keep Reading

PRESS RELEASE February 12, 2013

EpiCept Corporation and Immune Pharmaceuticals Amend Merger Agreement

HERZLIYA-PITUACH, Israel & TARRYTOWN, N.Y. –(BUSINESS WIRE)– Regulatory News : Immune Pharmaceuticals Ltd. (“Immune”), a privately held Israeli company, and EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT) announced today that they have executed an amendment to the Merger Agreement and Plan of Reorganization that they signed on November 7, 2012. Under the terms […]

Keep Reading

PRESS RELEASE February 6, 2013

EpiCept Corporation to Present at the 15th BIO CEO & Investor Conference

TARRYTOWN, N.Y.–(BUSINESS WIRE)– Regulatory News: EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT) announced today that Robert W. Cook, Interim President and Chief Executive Officer, will be presenting at the 15th BIO CEO & Investor Conference on Tuesday, February 12, 2013 at 2:30 PM local time at the Waldorf Astoria, Room Park South, in […]

Keep Reading

PRESS RELEASE January 9, 2013

Daniel Teper of Immune Pharmaceuticals to Present at the 6th Annual OneMedForum

TARRYTOWN, N.Y.–(BUSINESS WIRE)– Regulatory News: EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT) announced today that Daniel Teper, Chief Executive Officer of Immune Pharmaceuticals presented at the 6th Annual OneMedForum, on Wednesday, January 9, 2013 at 1:40 PM Pacific time at The Sir Francis Drake hotel in San Francisco, California. Mr. Teper presented a […]

Keep Reading

EVENT January 7, 2013

OneMedForum SF 2013

Jan 7-9th 2013 Following the New Year the Immune Team will be presenting at the OneMedForum in San Francisco.

Keep Reading